Clinical effectiveness and pharmacokinetics of gliflozin from the point of view of individual genetic characteristics: A review
- 作者: Golovina E.1, Vaizova O.1, Meleshko M.1, Samoilova I.1, Podchinenova D.1, Borozinets A.2, Matveeva M.1, Kudlay D.2,3
-
隶属关系:
- Siberian State Medical University
- Sechenov First Moscow State Medical University (Sechenov University)
- National Research Center – Institute of Immunology
- 期: 卷 95, 编号 8 (2023)
- 页面: 706-709
- 栏目: Reviews
- URL: https://journals.rcsi.science/0040-3660/article/view/148322
- DOI: https://doi.org/10.26442/00403660.2023.08.202326
- ID: 148322
如何引用文章
全文:
详细
A review of publications devoted to the analysis of genetic polymorphisms and features of the functioning of genes that affect the pharmacokinetics and pharmacodynamics of sodium-glucose cotransporter-2 inhibitors (SGLT2i) is presented. Objective of the study was to reveal information about genes whose polymorphism may affect the effectiveness of SGLT2i. The review was carried out in accordance with the PRISMA 2020 recommendations, the search for publications was carried out in the PubMed databases (including Medline), Web of Science, as well as Russian scientific electronic libraries eLIBRARY.RU from 1993 to 2022. Polymorphisms in the structure of several genes (SLC5A2, UGT1A9, ABCB1, PNPLA3) have been described that may affect the treatment of type 2 diabetes mellitus complicated by diseases such as chronic heart failure, chronic kidney disease, or non-alcoholic fatty liver disease. The information found on the genetic features of the development of the effects of SGLT2i is limited to a description of the differences in their pharmacokinetics. The relevance of currently available pharmacogenetic studies is largely constrained by small sample sizes.
作者简介
Evgenya Golovina
Siberian State Medical University
编辑信件的主要联系方式.
Email: golovina.el@ssmu.ru
ORCID iD: 0000-0001-6132-9617
канд. мед. наук, доц. каф. фармакологии ФГБОУ ВО СибГМУ
俄罗斯联邦, TomskOlga Vaizova
Siberian State Medical University
Email: golovina.el@ssmu.ru
ORCID iD: 0000-0003-4083-976X
д-р мед. наук, проф., проф. каф. фармакологии ФГБОУ ВО СибГМУ
俄罗斯联邦, TomskMarina Meleshko
Siberian State Medical University
Email: golovina.el@ssmu.ru
ORCID iD: 0000-0001-8405-5655
канд. биол. наук, доц. каф. фармакологии ФГБОУ ВО СибГМУ
俄罗斯联邦, TomskIuliia Samoilova
Siberian State Medical University
Email: golovina.el@ssmu.ru
ORCID iD: 0000-0002-2667-4842
д-р мед. наук, проф., зав. каф. педиатрии с курсом эндокринологии ФГБОУ ВО СибГМУ
俄罗斯联邦, TomskDaria Podchinenova
Siberian State Medical University
Email: golovina.el@ssmu.ru
ORCID iD: 0000-0001-6212-4568
канд. мед. наук, доц. каф. педиатрии с курсом эндокринологии ФГБОУ ВО СибГМУ
俄罗斯联邦, TomskAnastasiia Borozinets
Sechenov First Moscow State Medical University (Sechenov University)
Email: golovina.el@ssmu.ru
ORCID iD: 0009-0008-4980-1489
студентка 5-го курса Института клинической медицины им. Н.В. Склифосовского ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет)
俄罗斯联邦, MoscowMariia Matveeva
Siberian State Medical University
Email: golovina.el@ssmu.ru
ORCID iD: 0000-0001-9966-6686
д-р мед. наук, проф. каф. педиатрии с курсом эндокринологии ФГБОУ ВО СибГМУ
俄罗斯联邦, TomskDmitry Kudlay
Sechenov First Moscow State Medical University (Sechenov University); National Research Center – Institute of Immunology
Email: golovina.el@ssmu.ru
ORCID iD: 0000-0003-1878-4467
чл.-кор. РАН, д-р мед. наук, проф. каф. фармакологии Института фармации ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» (Сеченовский Университет), вед. науч. сотр. лаб. персонализированной медицины и молекулярной иммунологии №71 ФГБУ «ГНЦ “Институт иммунологии”»
俄罗斯联邦, Moscow; Moscow参考
- Imamovic Kadric S, Kulo Cesic A, Dujic T. Pharmacogenetics of new classes of antidiabetic drugs. Bosn J Basic Med Sci. 2021;21(6):659-71. doi: 10.17305/bjbms.2021.5646
- Российская ассоциация эндокринологов. Клинические рекомендации по лечению сахарного диабета 2 типа у взрослых. Режим доступа: https://cr.minzdrav.gov.ru/schema/290_2. Ссылка активна на 30.04.2023 [Rossiiskaia assotsiatsiia endokrinologov. Klinicheskie rekomendatsii po lecheniiu sakharnogo diabeta 2 tipa u vzroslykh. Available at: https://cr.minzdrav.gov.ru/schema/290_2. Accessed: 30.04.2023 (in Russian)].
- Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733-94. doi: 10.1152/physrev.00055.2009
- Салухов В.В., Халимов Ю.Ш., Шустов С.Б., Попов С.И. Ингибиторы SGLT2 и почки: механизмы и основные эффекты у больных сахарным диабетом 2 типа. Сахарный диабет. 2020;23(5):475-91 [Salukhov VV, Khalimov YuS, Shustov SB, Popov SI. SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients. Diabetes Mellitus. 2020;23(5):475-91 (in Russian)]. doi: 10.14341/DM12123
- Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol. 2018;14(12):1287-302. doi: 10.1080/17425255.2018.1551877
- Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018;61(10):2118-25. doi: 10.1007/s00125-018-4663-6
- Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019;18(4):295-311. doi: 10.1080/14740338.2019.1602116
- Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-46. doi: 10.1056/NEJMoa2024816
- Wells RG, Mohandas TK, Hediger MA. Localization of the Na+/glucose cotransporter gene SGLT2 to human chromosome 16 close to the centromere. Genomics. 1993;17(3):787-9. doi: 10.1006/geno.1993.1411
- Zimdahl H, Haupt A, Brendel M, et al. Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes. Pharmacogenet Genomics. 2017;27(4):135-42. doi: 10.1097/FPC.0000000000000268
- Enigk U, Breitfeld J, Schleinitz D, et al. Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis. Pharmacogenomics. 2011;12(8):1119-26. doi: 10.2217/pgs.11.69
- Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512-7. doi: 10.1038/nm.3828
- Ordelheide AM, Böhm A, Kempe-Teufel D, et al. Common variation in the sodium/glucose cotransporter 2 gene SLC5A2 does neither affect fasting nor glucose-suppressed plasma glucagon concentrations. PLoS One. 2017;12(5):e0177148. doi: 10.1371/journal.pone.0177148
- Gong QH, Cho JW, Huang T, et al. Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics. 2001;11(4):357-68. doi: 10.1097/00008571-200106000-00011
- Naagaard MD, Chang R, Någård M, et al. Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus. Br J Clin Pharmacol. 2022;88(4):1942-6. doi: 10.1111/bcp.15117
- Hoeben E, De Winter W, Neyens M, et al. Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus. Clin Pharmacokinet. 2016;55(2):209-23. doi: 10.1007/s40262-015-0307-x
- Francke S, Mamidi RN, Solanki B, et al. In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. J Clin Pharmacol. 2015;55(9):1061-72. doi: 10.1002/jcph.506
- Hodges LM, Markova SM, Chinn LW, et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011;21(3):152-61. doi: 10.1097/FPC.0b013e3283385a1c
- Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol. 2003;43:285-307. doi: 10.1146/annurev.pharmtox.43.100901.140233
- Hwang JG, Jeong SI, Kim YK, et al. Common ABCB1 SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject. Transl Clin Pharmacol. 2022;30(4):212-25. doi: 10.12793/tcp.2022.30.e23
- Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010;38(3):405-14. doi: 10.1124/dmd.109.029165
- Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004;14(3):147-54. doi: 10.1097/00008571-200403000-00002
- Mitsche MA, Hobbs HH, Cohen JC. Patatin-like phospholipase domain-containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets. J Biol Chem. 2018;293(18):6958-68. doi: 10.1074/jbc.RA118.002333
- Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138-53. doi: 10.1136/gutjnl-2017-313884
- Sumida Y, Seko Y, Yoneda M; Japan Study Group of NAFLD (JSG-NAFLD). Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res. 2017;47(4):266-80. doi: 10.1111/hepr.12856
- Eriksson JW, Lundkvist P, Jansson PA, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018;61(9):1923-34. doi: 10.1007/s00125-018-4675-2
- Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461-5. doi: 10.1038/ng.257